Self‐Gelling Powder Integrated with Multienzyme‐Like Nanozyme for the Management of Infected Diabetic Wounds
Advanced Healthcare Materials · 2026-03 · 15 (9)
DOI: 10.1002/adhm.202505045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 03.12.2025. Verfasst von Lei Yi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Burn, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Wound Healing, Anti-Bacterial Agents, Wound Infection. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Bacterial infection, hindered vascularization, excessive reactive oxygen species (ROS), and persistent inflammation are the intricate problems that delay infected diabetic wound repair. Herein, we constructed an in‐situ sprayed self‐gelling powder system (Vc‐Cu@CP) that is composed of carboxymethylcellulose sodium (CMC‐Na)/ ε ‐polylysine ( ε ‐PL) hydrogel (CP) and L‐Ascorbic acid‐stabilized multifunctional copper nanozymes (Vc‐Cu), with functions of exudate absorption and antibacterial for bacterial‐stained wound healing. Research demonstrated that an early acidic microenvironment with excessive ROS can activate POD‐mimic enzyme activity of Vc‐Cu nanozymes to kill bacteria through chemodynamic therapy. Furthermore, the microenvironment of chronic wounds triggers the SOD/CAT‐mimic cascade catalytic reaction of Vc‐Cu nanozymes, effectively scavenging ROS while providing oxygen. In vitro/in vivo studies revealed that the composite powder can quickly absorb wound exudate and transform into a hydrogel through intermolecular hydrogen bonds or electrostatic effects, facilitating the formation of a physical barrier and achieving in situ infected diabetic wound care. Additionally, RNA‐seq results illustrated that the self‐gelling powder upregulated genes related to wound healing and downregulated multiple signaling pathways related to inflammation and immune response, synergistically accelerating collagen deposition, angiogenesis, and epithelial regeneration. This study highlights the self‐gelling powder system (Vc‐Cu@CP) as a promising candidate for the management of complicated diabetic wounds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Burn, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Burn Surgery, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
- Joint Research Centre On Medicine, The Affiliated Xiangshan Hospital of Wenzhou Medical University, Ningbo, China.
- Zhejiang Engineering Research Center For Tissue Repair Materials, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang, China.
ORCID-Profile: Shixuan Chen
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Yi, L., Ji, C., Ye, J., Jiang, C., Zhang, Y., Chen, S., Xiao, S., & Cai, C. (2026). Self‐Gelling Powder Integrated with Multienzyme‐Like Nanozyme for the Management of Infected Diabetic Wounds. Advanced Healthcare Materials, 15(9). https://doi.org/10.1002/adhm.202505045
Vancouver
Yi L, Ji C, Ye J, Jiang C, Zhang Y, Chen S, et al. Self‐Gelling Powder Integrated with Multienzyme‐Like Nanozyme for the Management of Infected Diabetic Wounds. Advanced Healthcare Materials. 2026;15(9). doi:10.1002/adhm.202505045
BibTeX
@article{Yi2026,
author = {Yi, Lei and Ji, Chao and Ye, Jiaole and Jiang, Chubing and Zhang, Yun and Chen, Shixuan and Xiao, Shichu and Cai, Chao},
title = {Self‐Gelling Powder Integrated with Multienzyme‐Like Nanozyme for the Management of Infected Diabetic Wounds},
journal = {Advanced Healthcare Materials},
year = {2026},
volume = {15},
number = {9},
doi = {10.1002/adhm.202505045}
}
EUVIMED